Ensoma
BOSTON, MA · Biotechnology, Health Care · 101 employees
Ensoma is developing potentially curative medicines for genetic diseases, immune disorders and cancer through in vivo hematopoietic stem cells (HSCs) engineering. Our platform combines proprietary base editing or high-efficiency gene integration systems with high-capacity virus-like particles (VLPs) toward our goal of providing one-time administration of durable genetic medicines. The delivery sys
Funding history
- Funding Round — $53.0M — Sep 2025
- Venture - Series Unknown — $129.0M — May 2023
- Venture - Series Unknown — $79.0M — Jan 2023
- Funding Round — $85.0M — Jan 2023
- Venture - Series Unknown — $129.0M — Feb 2021
Recent signals
- Sep 22, 2025: Raised $53.0M in Funding Round
- Oct 28, 2024: Ensoma Appoints Jon Garen as Chief Corporate Development and Business Officer
- May 23, 2023: Raised $129.0M in Venture - Series Unknown
- Jan 09, 2023: Raised $79.0M in Venture - Series Unknown
- Jan 05, 2023: Raised $85.0M in Funding Round
- Jan 05, 2023: Acquired Ensoma Announces $85 Million Financing And Agreement To Acquire Twelve Bio To Advance Portfolio Of In Vivo Engineered Cellular Medicines
- Feb 19, 2021: Raised $129.0M in Venture - Series Unknown
See plans & pricing → Track Ensoma’s funding, hiring, and signals — with verified contacts — on Fundz.